

## Next Generation Tissue Diagnostics

**Tissue diagnostics** is a key enabler of personalized medicine. The increasing number of cancer cases multiplied by the growing number of tests required per patient exploded the need for such tests. However, current slow and inefficient technologies cannot answer this need.

**Who is Lunaphore?** We build laboratory automation systems for tissue diagnostics, based on a unique microfluidic technology.

Our mission is to disrupt the field by fundamentally changing the time & resource driven nature of tissue biomarker tests.




### Fastest system for tissue diagnostics

#### Shortest turn-around-time

30 min vs. 3h30 market leader  
>2x lab productivity: a patient case in 2 hours

#### Highest throughput

5x compared to market leader  
5 to 10x less equipment is needed



### Best assay automation technology

#### Medical Value

Unique quantitative staining

#### Highest quality assays

Reproducible and uniform assays with definitive border  
No oil, coverglass or cross-contamination.

### High-growth market

The tissue diagnostics market is projected to double within the next 5 years due to an increasing need for personalized medicine.



### FOUNDERS

#### Dr. Ata Tuna Ciftlik, CEO, Chairman

- 10+ years exp. in biomedical microsystems development
- >20 publications & 6 patents

#### Dr. Diego G. Dupouy, CTO

- 6+ years exp. in microfluidic diagnostic systems
- 12 publications & 3 patents
- Previously at IBM Research California

#### Déborah Heintze, COO

- 4+ years experience
- Bioengineer EPFL & Harvard-MIT division of health sciences
- Previously at EPFL Tech Transfer

### TEAM STATISTICS

#### Core Team

14 FTEs: 60 years combined experience  
5 PhDs, 8 MSc.

#### Collaborative Research Team

5 FTEs: 3 Post-Docs, 2 PhD students

#### Advisory Board & Consultants

6 Advisors - 100+ years combined exp.  
Manufacturing, Sales & Marketing, Finance, Pathology

4 Consultants - 50+ years combined exp.  
Regulatory, Legal, IP, and Management

### IP & CLINICAL DATA

#### 4 patents & 2 trademarks

Microfluidic tissue processor is protected by portfolio of 4 patents.

#### Clinical Data

Published data with 100+ patients  
3 Publications in top-notch journals

#### Field Tested

With 200+ cases at 10 different sites.

### FINANCIALS

**Raised so far** CHF 6M  
Now closing CHF 3.7 M 2017Q1

**Open**  
Series B CHF 10 M 2018Q2